MyelofibrosisCYT387 (oral) monotherapy
Study Design: dose-escalation with cohort expansion at biologically active doses
Primary Endpoints: dose-limiting toxicities, maximum tolerated dose, safety and tolerability
Secondary Endpoints: effect on spleen size, hematological symptoms, quality of life, markers of aberrant JAK2 activity in blood
# Patients: 166 (enrollment complete)
Trial Location: United States, Australia
Lead Sponsor: YM BioSciences Australia
|
|
|
|
|
MyelofibrosisCYT387 (oral) monotherapy BID
Study Design: (Part 1) dose-escalation enrolling successive patient cohorts dosed starting at 200mg BID, escalating at 50mg BID per cohort; (Part 2) dose-confirmation evaluating patients at or below MTD determined in Part 1
Primary Endpoints: maximum tolerated dose, safety and tolerability, efficacy
# Patients: 60 (enrollment ongoing)
Trial Location: United States, Canada
Lead Sponsor: YM BioSciences Australia
|
|
|
|
|
